Drugs › Histamine-2 receptor antagonist
Generic name
Famotidine: adverse event reports filed with FDA
6,009 reports list it as a suspect or interacting product, 2004–2026. Class: Histamine-2 receptor antagonist. Also reported as Famotidine Tablets Usp, Famotidine Tablets Usp 20mg, Famotidine Tablets 40mg.
- 6,009
- reports as suspect product
- 0% of all reports · about 267 a year
- 687
- reports, 12 months to June 2026
- 797 in the 12 months before
- 64.6%
- marked serious by the reporter
- 96.3% across the class
- 9.2%
- record death among outcomes, as reported
- 552 reports · not verified by FDA
Between January 2004 and June 2026, 6,009 adverse event reports received by FDA list famotidine, a generic name as a suspect or interacting product. Reports that mention it only as a concomitant medication (70,631) are left out of every figure here.
In the 12 months to June 2026, 687 reports listed it, down 14% from 797 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 267 reports a year and 0% of the 20,646,523 reports in the database, and 2.2% of the reports for the histamine-2 receptor antagonist class. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are drug ineffective (16.3%), off label use (6.6%) and nausea (4.4%). A report can list several reactions, so shares add to more than 100%; 1,134 different terms appear across these reports. Drug ineffective is recorded in 16.3% of these reports, about the same share as in the median histamine-2 receptor antagonist drug (15.3%).
64.6% of the reports are marked serious by the reporter (96.3% across the class); 9.2% record death among the outcomes and 28.3% record hospitalisation, as reported. 37% of the reports came from consumers, and the largest patient age group is 45 to 64 (21.1%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Famotidine reports recording the termmedian drug in histamine-2 receptor antagonist
- Drug ineffectivethe medicine did not work as expected16.3%982
- Off label useused for a purpose or in a way not on the label6.6%395
- Nauseafeeling sick4.4%265
- Drug interactionan interaction between medicines3.8%229
- Anaphylactic reactiona severe, sudden allergic reaction3.6%218
- Dizzinesslight-headedness or unsteadiness3.6%216
- Diarrhoealoose or frequent stools3.4%205
- Fatiguetiredness3.2%193
- Vomitingbeing sick3%181
- Condition aggravatedthe condition being treated got worse2.9%176
- Pyrexiafever2.8%171
- Completed suicidedeath by suicide2.7%165
- Headachehead pain2.6%159
- Toxicity to various agentspoisoning or toxic effect of one or more substances2.6%158
- Dyspnoeashortness of breath2.6%157
- Urticariahives2.5%148
- Pneumonialung infection2.3%141
- Confusional stateconfusion2%123
- Drug hypersensitivityan allergic-type reaction to a medicine2%123
- Product use in unapproved indicationused for a purpose not on the label2%123
- Hypersensitivityan allergic-type reaction2%121
- Tachycardiafast heart rate2%118
- Abdominal pain upperupper stomach pain1.8%110
- Pruritusitching1.8%110
- Rashskin rash1.8%106
- Incorrect dose administeredthe wrong dose was given1.7%101
- Malaisegeneral feeling of being unwell1.6%97
- Hypotensionlow blood pressure1.6%96
- Decreased appetitereduced appetite1.5%93
Top 30 of 1,134 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 8 drugs in the histamine-2 receptor antagonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 270,928 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 64.9% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Gastrooesophageal reflux disease | 579 | 9.6% |
| Dyspepsia | 335 | 5.6% |
| Premedication | 148 | 2.5% |
| Prophylaxis | 121 | 2% |
| Mast cell activation syndrome | 76 | 1.3% |
| Gastritis | 59 | 1% |
The indication field is filled in by the reporter and is often blank; shares are of all 6,009 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Famotidine reports |
|---|---|---|
| Acetaminophen | 383 | 6.4% |
| Ondansetron | 372 | 6.2% |
| Dexamethasone | 322 | 5.4% |
| Diphenhydramine | 310 | 5.2% |
| Omeprazole | 309 | 5.1% |
| Amlodipine | 290 | 4.8% |
| Gabapentin | 278 | 4.6% |
| Aspirin | 277 | 4.6% |
| Furosemide | 277 | 4.6% |
| Montelukast | 277 | 4.6% |
Other products listed in reports where Famotidine is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Famotidine | Histamine-2 receptor antagonist | All reports |
|---|---|---|---|
| Reports as suspect product | 6,009 | 270,928 | 20,646,523 |
| Share of that pool | — | 2.2% | 0% |
| Reports, latest 12 months | 687 | — | 1,332,454 |
| Marked serious | 64.6% | 96.3% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 92 | 71 | 91 |
| Hospitalisation recorded, per 1,000 reports | 283 | 36 | 213 |
| Consumer-filed share | 37% | 42.4% | 45.8% |
| Top term, share of reports | Drug ineffective 16.3% | median 15.3% | 6.3% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the histamine-2 receptor antagonist class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Ranitidine | generic | 195,204 | 269 | 99.1% |
| Ranitidine hydrochloride | generic | 63,047 | 463 | 97.4% |
| Pepcid | brand | 2,589 | 122 | 42.7% |
| Pepcid Complete | brand | 1,219 | 80 | 8.1% |
| Cimetidine | generic | 1,121 | 40 | 84.5% |
| Pepcid AC | brand | 1,096 | 77 | 15.1% |
| Pepcid Ac Maximum Strength | brand | 643 | 28 | 3.6% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Famotidine reports
How many adverse event reports has FDA received for Famotidine?
6,009 reports list Famotidine as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 687 of them arrived in the latest 12 months. Another 70,631 list it only as a concomitant medication.
What reactions are recorded in Famotidine reports?
drug ineffective (16.3%), off label use (6.6%), nausea (4.4%), drug interaction (3.8%) and anaphylactic reaction (3.6%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Famotidine was responsible.
How serious are the reports?
64.6% are marked serious by the reporter. Among the outcomes recorded, 9.2% of reports include death and 28.3% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (37%), other health professional (25.6%) and physician (23.7%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Famotidine rising?
687 reports in the 12 months to June 2026, down 14% from 797 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Famotidine was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Famotidine?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Famotidine as a suspect or interacting product; reports listing it only as a concomitant medication (70,631) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.